QC
TNGX icon

Quadrature Capital’s Tango Therapeutics TNGX Stock Holding History

Quadrature Capital’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36,189
Closed -$303K – 1652
2025
Q3 		$303K Buy
+36,189
New +$245K ﹤0.01% 668

Other funds holding TNGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Quadrature Capital's TNGX Position: Q4 2025 in Review

Quadrature Capital sold out of Tango Therapeutics (TNGX) in Q4 2025, closing a stake of 36,189 shares — an estimated $303K sold.

Quadrature Capital first reported a position in TNGX in Q3 2025 and held it in 1 quarter. The position peaked at $303K in Q3 2025. 170 funds tracked by Wall St. Rank hold TNGX as of Q4 2025.

  • Quadrature Capital reported no remaining Tango Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 36,189 Tango Therapeutics shares in Q4 2025, an estimated $303K.
  • Quadrature Capital first reported a position in Tango Therapeutics in Q3 2025 and held it in 1 quarter.
  • Quadrature Capital's Tango Therapeutics position peaked at $303K in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.